Please assess the completion status of the following clinical trial:

Trial Title: Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient or designated proxy willing and able to provide informed consent prior to enrollment in the study.~* COVID-19 PCR positive on nasopharyngeal swab~* Aged \>/= 18 years old~* Patient hospitalized with newly diagnosed documented severe COVID-19 infection: with respiratory rate \>/= 30 breaths/min OR peripheral capillary oxygen saturation (SpO2) \< 93% on room air for nonintubated pts.~* Fever of 38.5 C or suspected respiratory infection~* IL-6 level \>/= 80 pcg/ml~* Cohort #1 - non intubated Cohort #2 - intubated~* Women of childbearing potential must have a negative serum or urine pregnancy test~* Patients receiving ongoing steroid therapy are eligible~* Patients will be allowed to receive concurrent or sequential treatment with remdesivir~Exclusion Criteria:~* Patients with uncontrolled systemic fungal and bacterial infections~* Patients with latent tuberculosis~* Patients with known hypersensitivity to tocilizumab or any component of the formulation~* Concurrent initiation of steroid therapy is not allowed~* Patients with uncrontroled malignant disease, with a life expectancy of 3 months or less

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intubation/Mechanical Ventilation (Type: EXPERIMENTAL): Progression of respiratory failure in cohort #1 will be defined as a sustained increase in oxygen requirement or need for intubation/mechanical ventilation
- Respiratory Support (Type: EXPERIMENTAL): In cohort #2 progression of respiratory failure will be defined as a need for increasing respiratory support (e.g. FiO2 or PEEP)

Based on this trial design, predict the completion outcome and termination type (if applicable).